Abstract
Background: Despite Pembrolizumab is the new standard of care in metastatic NSCLC with PD-L1 >50%, it was recognized not all patients benefit from it. PET imaging plays an important role in assessing the biologic behavior of NSCLC and defining response to therapy. We explored the predictive values of both the lymphocyte-monocyte ratio (LMr) in peripheral blood and baseline SUVmax of 18F-fluorodeoxyglucose by the primary tumor in positron emission tomography/computed tomography (PET/CT) in patients with metastatic NSCLC treated with Pembrolizumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
